Table 1.
Summary of clinical and pathological features of the studied early-stage ER+, LN− breast cancer cohorts
| All data sets, N (%) | Modeling set, N (%) | Test set, N (%) | P value* | |
|---|---|---|---|---|
| No. of patients | 276 | 177 | 99 | |
| Age | 59.0±11.9 | 60.4±11.2 | 56.5±12.2 | ϒ0.0105 |
| Race | <0.0001 | |||
| White | 259 (93.8) | 175 (98.9) | 84 (84.9) | |
| Other | 17 (6.2) | 2(1.1) | 15 (15.1) | |
| Histology grade | 1 | |||
| Well/moderately differentiated | 39 (60.9) | 1 (50.0) | 38 (61.3) | |
| Poorly differentiated | 25 (39.1) | 1 (50.0) | 24 (38.7) | |
| Histology grade | ||||
| Well differentiated | 8 (12.5) | 1 (50.0) | 7 (11.3) | 0.2361 |
| Moderately/poorly differentiated | 56 (87.5) | 1 (50.0) | 55 (88.7) | |
| Nuclear grade | 0.0056 | |||
| 1/2 | 197 (89.9) | 132 (86.3) | 65 (98.5) | |
| 3 | 22 (10.1) | 21 (13.7) | 1 (1.5) | |
| Nuclear grade | 0.4091 | |||
| 1 | 60 (27.4) | 39 (25.5) | 21 (31.8) | |
| 2/3 | 159 (72.6) | 114 (74.5) | 45 (68.2) | |
| T-stage | <0.0001 | |||
| T1 | 248 (89.9) | 172 (97.2) | 76 (76.8) | |
| T2 | 28 (10.1) | 5 (2.8) | 23 (23.2) | |
| Her2 status | 0.0336 | |||
| Positive | 94 (34.4) | 69 (39.0) | 25 (26.0) | |
| Negative | 179 (65.6) | 108 (61.0) | 71 (74.0) | |
| Chemotherapy | <0.0001 | |||
| Yes | 25 (9.1) | 0 (0.0) | 25 (25.3) | |
| No | 251 (90.9) | 177 (100.0) | 74 (74.7) | |
| Survival status | 0.0588 | |||
| Long term (≥10 years) | 150 (54.4) | 104 (58.8) | 46 (46.5) | |
| Short term (<10 years) | 126 (45.6) | 73 (41.2) | 53 (54.5) |
*
P values were calculated from two-sided Fisher’s exact test.
ϒ
P value was calculated from Welch two sample t test. P values are computed between the modeling and test set. Values in bold are statistically significant, p < 0.05